N
Naoki Niikura
Researcher at Tokai University
Publications - 107
Citations - 1937
Naoki Niikura is an academic researcher from Tokai University. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 17, co-authored 78 publications receiving 954 citations. Previous affiliations of Naoki Niikura include Kyoto University.
Papers
More filters
Journal ArticleDOI
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Shanu Modi,William Jacot,Toshinari Yamashita,Joohyuk Sohn,Maria Vidal,Eriko Tokunaga,Junji Tsurutani,Naoto Ueno,Aleix Prat,Yee Soo Chae,Keun Seok Lee,Naoki Niikura,Yeon Hee Park,Bing Xue,Xiao-juan Wang,Miguel Gil-Gil,Wei Liu,Jean-Yves Pierga,Seock-Ah Im,Halle C. F. Moore,Hope S. Rugo,Rinat Yerushalmi,Flora Zagouri,Andrea Gombos,Sung-Bae Kim,Qiang Liu,Ting Luo,Cristina Saura,Peter Schmid,Tao Sun,Dhiraj Gambhire,Lotus Yung,Yibin Wang,Jasmeet Singh,Patrik Vitazka,Gerold Meinhardt,Nadia Harbeck,David Cameron +37 more
TL;DR: In this phase 3 trial involving patients with HER2-low metastatic breast cancer, trastuzumab deruxtecan resulted in significantly longer progression-free and overall survival than the physician's choice of chemotherapy.
Journal ArticleDOI
Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis
Naoki Niikura,Naoki Niikura,Naoki Hayashi,Norikazu Masuda,Seiki Takashima,R. Nakamura,Ken-ichi Watanabe,Chizuko Kanbayashi,Mayumi Ishida,Yasuo Hozumi,Michiko Tsuneizumi,Naoto Kondo,Yoichi Naito,Yayoi Honda,Akira Matsui,Tomomi Fujisawa,Risa Oshitanai,Hiroyuki Yasojima,Yutaka Tokuda,Shigehira Saji,Hiroji Iwata +20 more
TL;DR: The prognosis and clinical course of patients with brain metastasis from breast cancer before and after developing brain metastases vary according to subtype, and focusing on the subtypes of breast cancer can optimize the prevention, early detection, and improved treatment ofbrain metastases.
Journal ArticleDOI
Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients
Rin Ogiya,Naoki Niikura,Nobue Kumaki,Giampaolo Bianchini,Shigehisa Kitano,Takayuki Iwamoto,Naoki Hayashi,Kozue Yokoyama,Risa Oshitanai,Mayako Terao,Toru Morioka,Banri Tsuda,Takuho Okamura,Yuki Saito,Yasuhiro Suzuki,Yutaka Tokuda +15 more
TL;DR: Tumors at first metastatic recurrence in HER2+ and TN breast cancers have a lower percentage of TILs and CD8+ and CD4+ T cells compared to primary tumors, which indicates that immune escape plays a role in tumor progression.
Journal ArticleDOI
Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21 755 patients from the Japanese breast cancer registry
Naoki Niikura,Ai Tomotaki,Hiroaki Miyata,Takayuki Iwamoto,Masaaki Kawai,Keisei Anan,Naoki Hayashi,Kenjiro Aogi,Takanori Ishida,Hideji Masuoka,Kotaro Iijima,Shinobu Masuda,K. Tsugawa,Takayuki Kinoshita,Seigo Nakamura,Yutaka Tokuda +15 more
TL;DR: The data strongly support the need for retest ER, PgR, HER2 of surgical sample after neoadjuvant therapy in order to accurately determine appropriate use of targeted therapy and confirmed that loss of HER2-positive status can occur after neoadedjuvant treatment in patients with primary HER1-positive breast cancer.
Journal ArticleDOI
Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers
Mitsuya Itoh,Takayuki Iwamoto,Junji Matsuoka,Tomohiro Nogami,Takayuki Motoki,Tadahiko Shien,Naruto Taira,Naoki Niikura,Naoki Hayashi,Shoichiro Ohtani,Kenji Higaki,Toshiyoshi Fujiwara,Hiroyoshi Doihara,W. Fraser Symmans,Lajos Pusztai +14 more
TL;DR: A second RNA-based assessment may help identifying the minority of ESR1 mRNA-positive, luminal-type cancers and the safest clinical approach may be to consider both adjuvant endocrine and chemotherapy.